ObjectiveTo observe the effects of Shenlingcao oral liquid on HIV-RNA load, CD4+ T cells of HIV carriers. MethodsWe included asymptomatic HIV-infection people from February to April 2012, gave them Shenlingcao oral liquid for oral intake (1 bottle/d, 200 mL/bottle) during 6 months, and observed the changes of HIV-RNA load and CD4+ T cell at different time points (before intake, 2 months, 4 months, and 6 months). ResultsA total of 25 cases were included. The results showed that a tendency existed that CD4+ T cells counts gradually increased along with time; HIV-RNA load did not change regularly; and the total effective rate was steady; and the cases in steady status tended to increase. ConclusionShenlingcao oral liquid is beneficial to the improvement of the immunity of asymptomatic HIV-infected people. Because of limited sample size and study design, the above conclusion should be verified by further conducting large-scale high quality randomized controlled trials.
ObjectiveTo observe intervention effect of Shenlingcao oral liquid on asymptomatic chronic hepatitis B virus carriers (AsC). MethodsA self control before-after trial was conducted in the First Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine and the Ninth People's Hospital of Nanchang City from November 2011 to May 2012. A total of 64 AsCs were treated by Shenlingcao oral liquid (1 bottle/d, 200 mL, once daily for 6 months). Serum HBV viral load, six specific serum markers of HBV and 11 liver function index were tested and recorded before and at the 1th, 3th, 6th months of the treatment. Analysis of variance of repeated data was conducted. ResultsAfter one month of the treatment, 35/57 (61.40%) AsCs' serum HBV-DNA loads decreased, 1 log decrease was observed in 15 cases, 2 log decrease was observed in 4 cases, and decrease under the detection limit was observed in 12 cases. 41/57 (71.93%) AsCs' serum HBV-DNA loads decreased after 3 months of treatment, 1 log decrease was observed in 21 cases, 2 log decrease was observed in 5 cases, and decrease under the detection limit was observed in 15 cases. 31/49 (63.26%) AsCs' serum HBV-DNA loads decreased after 6 months of the treatment, 1 log decrease was observed in 19 cases, decrease more than 2 log was observed in 7 cases, and decrease under the detection limit was observed in 12 cases. The serum HBV viral loads at different time points of the treatment were significantly different (P<0.001). As medication time went, AsCs' serum HBV viral loads presented a decrease trend after taking Shenlingcao oral liquid, especially obvious at the 3th month. ConclusionShenlingcao oral liquid could help promote AsCs' ability of clearing virus and controlling serum HBVDNA loads.